65,437 trials
Acne Vulgaris
Primary: Percent Change in the Inflammatory (Papules and Pustules) Lesion Counts — -48.25; -52.72; -45.03 Percent change in inflammatory lesions
Breast Diseases
Primary: Number of Participants Considered to Have a Successful Surgery — 34 Participants
Diabetic Nephropathy
Primary: "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)" — 146; 116 Participants — p=<0.05
IUD Not Visible
Primary: Number of Participants Who Had IUD Removed Within 6 Months — 6; 8 Participants — p=0.51
Brain and Central Nervous System Tumors
Primary: Feasibility
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 105; 101 Participants
Clostridium Difficile Infection
Primary: Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks — 112; 23; 30; 52 Participants
Non-Small Cell Lung Cancer
Primary: Time to Progression-Free Survival (PFS) — 7.9 months
Gastric or Gastroesophageal Junction Adenocarcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Phase 1b — 6; 2 Participants
Otomycosis
Primary: Primary Efficacy Endpoint — 1; 3; 1 Participants
Cholestasis
Primary: Number of Participants With a Change in Conjugated/Direct Bilirubin — 4 Participants
Systemic Sclerosis · Scleroderma
Primary: Number of Participants Who Experience Grade 3 or Higher Adverse Events That Occur at or Before Week 24 — 0; 0 Participants
Polycystic Ovary Syndrome
Primary: Mean Overnight Growth Hormone Levels — 0.85; 0.84 ng/mL — p=0.918
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Multiple Sclerosis
Primary: The Number of Participants Completing at Least 80% of the Targeted Sessions. — 15; 12 participants